New potential therapeutic modalities: aPC

Sepsis

Volumn 3, Issue 2, 1999, Pages 161-171

  Esmon, Charles T ^a,b,c  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Disseminated intravascular coagulation; Protein C; Protein S; Sepsis; Shock; Thrombin; Thrombomodulin

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN S; THROMBOMODULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACTIVITY; HUMAN; NONHUMAN; SEPSIS; SEPTIC SHOCK;

EID: 0033495730     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009859702238     Document Type: Article

References (138)

1. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995;5:141-148.
2. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995;9:946-955.
3. Esmon CT, Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 1995;6:259-268.
4. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated protein C and its analogy with factor V. Blood 1984;63:486-489.
5. Koedam JA, Meijers JCM, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988;82:1236-1243.
6. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986;25:505-512.
7. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-1993.
8. Halbmayer W-M, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994;5:51-57.
9. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
10. Dahlbäck B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994;94:923-927.
11. Dahlbäck B. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991;66:49-61.
12. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 1991; 30:10363-10370.
13. Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J 1992;6:2561-2567.
14. Pabinger I, Brucker S, Kyrle PA, Schneider B, Korninger HC, Niessner H, Lechner K. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coag Fibrinol 1992;3: 547-553.
15. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993;289:313-330.
16. Alving BM, Comp PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol 1992;167:1184-1191.
17. Reitsma PH, Poort SR, Bernardi F, Gandrille S, Long GL, Sala N, Cooper DN. Protein C deficiency: A database of mutations. For the Protein C & S Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993;69:77-84.
18. Castellino FJ. Human protein C and activated protein C. Trends Cardiovasc Med 1995;5:55-62.
19. Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR, Saito H, Sala N, Witt I, Cooper DN. Protein C deficiency: A database of mutations, 1995 update. Thromb Haemost 1995;73:876-879.
20. Florell SR, Rodgers GM. Inherited thrombotic disorders: An update. Am J Hematol 1997;54:53-60.
21. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993;92:2003-2012.
22. Laszik Z, Mitro A, Taylor FB, Jr, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway. Circulation 1997;96:3633-3640.
23. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985;101:363-371.
24. McCachren SS, Diggs J, Weinberg JB, Dittman WA. Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood 1991;78: 3128-3132.
25. Satta N, Freyssinet J-M, Toti F. The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccaride. Br J Haematol 1997;96:534-542.
26. Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994;269:26486-26491.
27. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996;93:10212-10216.
28. Xu J, Esmon NL, Esmon CT. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J Biol Chem 1999;274:6704-6710.
29. Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H, Kimoto M. Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med 1998;187: 1029-1035.
30. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989;264: 4743-4746.
31. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995;270:25336-25339.
32. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994;18735-18738.
33. Zoller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-2524.
34. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995;85:3405-3411.
35. Guinto ER, Esmon CT. Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 1984;259:13986-13992.
36. Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest 1982;70:127-134.
37. Gruber A, Griffin JH, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989;73:639-642.
38. España F, Gruber A, Heeb MJ, Hanson SR, Harker LA, Griffin JH. In vivo and in vitro complexes of activated protein C with two inhibitors in baboons. Blood 1991;77:1754-1760.
39. Gruber A, Harker LA, Hanson SR, Kelly AB, Griffin JH. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation 1991;84: 2454-2462.
40. Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, Okabe H, Takatsuki K, Aoki N. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 1990;63:48-53.
41. Scully MF, Toh CH, Hoogendoorn H, Manuel RP, Nesheim ME, Solymoss S, Giles AR. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, α1-antitrypsin and α2-macroglobulin, in patients with disseminated intravascular coagulation. Thromb Haemost 1993;69: 448-453.
42. Heeb MJ, Espanña F, Griffin JH. Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood 1989;73:446-454.
43. 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem 1991;266:17606-17612.
44. Giri TK, Hillarp A, Härdig Y, Zöller B, Dahlbäck B. A new direct, fast and quantitative enzyme-linked ligandsorbent assay for measurement of free protein S antigen. Thromb Haemost 1998;79:767-772.
45. de Munk GAW, Groeneveld E, Rijken DC. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. J Clin Invest 1991;88:1680-1684.
46. Molinari A, Giogetti C, Lansen J, Vaghi F, Orsini G, Faioni EM, Mannucci PM. Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator in vitro and in a perfused rabbit heart model. Thromb Haemost 1992;67:226-232.
47. Kishida A, Ueno Y, Maruyama I, Akashi M. Immobilization of human thrombomodulin onto biomaterials. Comparison of immobilzation methods and evaluation of antithrombogenicity. ASAIO J 1994;40:M840-M845
48. Gonda Y, Hirata S, Saitoh K-I, Aoki Y, Mohri M, Gomi K, Sugihara T, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats. Thromb Res 1993;71:325-335.
49. Nawa K, Itani T, Ono M, Sakano K, Marumoto Y, Iwamoto M. The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation. Thromb Haemost 1992;67:366-370.
50. Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 1995;74: 1265-1270.
51. Aoki Y, Takei R, Mohri M, Gonda Y, Gomi K, Sugihara T, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats. Am J Hematol 1994;47:162-166.
52. Solis MM, Cook C, Cook J, Glaser C, Light D, Morser J, Yu S, Fink L, Eidt JF. Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model. J Vasc Surg 1991;14:599-604.
53. Solis MM, Vitti M, Cook J, Young D, Glaser C, Light D, Morser J, Wydro R, Yu S, Fink L, Eidt JF. Recombinant soluble human thrombomodulin: A randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model. Thromb Res 1994; 73:385-394.
54. Manco-Johnson MJ, Abshire TC, Jacobson LJ, Marlar RA. Severe neonatal protein C deficiency: Prevalence and thrombotic risk. J Pediatr 1991;119:793-798.
55. Seligsohn U, Berger A, Abend M, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive thrombosis in the newborn. N Engl J Med 1984;310:559-562.
56. Sills RH, Marlar RA, Montgomery RR, Desphande GN, Humbert JR. Severe homozygous protein C deficiency. J Pediatr 1984;105:409-413.
57. Mahasandana C, Suvatte V, Chuansumrit A, Marlar RA, Manco-Johnson MJ, Jacobson LJ, Hathaway WE. Homozygous protein S deficiency in an infant with purpura fulminans. J Pediatr 1990;117:750-753.
58. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Sem Thromb Hemost 1990;16:299-309.
59. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planché C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991;325:1565-1568.
60. Broekmans AW, Bertina RM, Loeliger EA, Hofman V, Klingeman HG. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost 1983; 49:251 (Letter).
61. Conard J, Horellou MH, van Dreden P, Samama M, Reitsma PH, Poort S, Bertina RM. Homozygous protein C deficiency with late onset and recurrent coumarin-induced skin necrosis. Lancet 1992;339:743-744.
62. Alhenc-Gelas M, Emmerich J, Gandrille S, Aubry ML, Benaily N, Fiessinger JN, Aiach M. Protein C infusion in a patient with inherited protein C deficiency caused by two missense mutations: Arg 178 to Gln and Arg-1 to His. Blood Coag Fibrinol 1995;6:35-41.
63. Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol 1993;129:753-756.
64. Powars D, Larsen R, Johnson J, Hulbert T, Sun T, Patch MJ, Francis R, Chan L. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency. Clin Infect Dis 1993;17:254-261.
65. Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ. Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 1982;60: 261-264.
66. Heeb MJ, Mosher D, Griffin JH. Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation. Blood 1989;73:455-461.
67. Taylor FB Jr, He SE, Chang ACK, Box J, Ferrell G, Lee D, Lockhart M, Peer G, Esmon CT. Infusion of phospholipid vesicles amplifies the local thrombotic response to TNF and anti-protein C into a consumptive response. Thromb Haemost 1996;75:578-584.
68. Healy AM, Rayburn HB, Rosenberg RD, Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995;92: 850-854.
69. Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998;101: 1983-1991.
70. Öhlin A-K, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 1995;85:330-336.
71. Öhlin A-K, Norlund L, Marlar RA. Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997;78:396-400.
72. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations in myocardial infarction. Circulation 1997;96:15-18.
73. 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost 1998;80: 743-748.
74. Kumada T, Dittman WA, Majerus PW. A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 1987;71:728-733.
75. Griffin JH, Gruber A, Fernandez JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992;79:3203-3211.
76. Dahlbäck B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem 1986;261:12022-12027.
77. Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984;74:2082-2088.
78. Wiedmer T, Esmon CT, Sims PJ. On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity. J Biol Chem 1986;261:14587-14592.
79. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66:67-79.
80. Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coag Fibrinol 1993;4:281-292.
81. Morrissey JH, Drake TA. Procoagulant response of the endothelium and monocytes in Pathophysiology of Shock, Sepsis and Organ Failure. Springer-Verlag, 1993:564-574.
82. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscl Thromb 1992;12:1111-1121.
83. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79:124-130.
84. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745.
85. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460-3464.
86. Tsuchida A, Salem H, Thomson N, Hancock WW. Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression. J Exp Med 1992;175:81-90.
87. Ohdama S, Matsubara O, Aoki N. Plasma thrombomodulin in Wegener's granulomatosis as an indicator of vascular injuries. Chest 1994;106:666-671.
88. Labarrere CA, Esmon CT, Carson SD, Faulk WP. Concordant expression of tissue factor and Class II MHC antigens in human placental endothelium. Placenta 1990;II:309-318.
89. Laszik Z, Carson CW, Nadasdy T, Johnson LD, Lerner MR, Brackett DJ, Esmon CT, Silva FG. Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy. Lab Invest 1994;70: 862-867.
90. Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal E. coli sepsis. Am J Pathol 1993;142:1458-1470.
91. Kapiotis S, Besemer J, Bevec D, Valent P, Bettelheim P, Lechner K, Speiser W. Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. Blood 1991;78:410-415.
92. Dittman WA, Nelson SC, Greer PK, Horton ET, Palomba ML, McCachren SS. Characterization of thrombomodulin expression in response to retinoic acid and identification of a retinoic acid response element in the human thrombomodulin gene. J Biol Chem 1994;269:16925-16932.
93. Koyama T, Hirosawa S, Kawamata N, Tohda S, Aoki N. All-trans retinoic acid upregulates thrombomodulin and down regulates tissue-factor expression in acute promyelocytic leukemia cells: Distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 1994;84: 3001-3009.
94. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990;76:2024-2029.
95. Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy. Clin Chem 1991;37:269-272.
96. Takahashi H, Hanano M, Wada K, Tatewaki W, Niwano H, Tsubouchi J, Nakano M, Nakamura T, Shibata A. Circulating thrombomodulin in thrombotic thrombocytopenic purpura. Am J Hematol 1991;38:174-177.
97. Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T. Plasma levels of soluble thrombomodulin increase in cases of disseminated intravascular coagulation with organ failure. Am J Hematol 1991;38:281-287.
98. Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992;39:20-24.
99. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: Comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol 1992;41:32-39.
100. Boehme MWJ, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP. Release of thrombomodulin from endothelial cells by concerted action of TNF-α and neutrophils: In vivo and in vitro studies. Immunology 1996;87:134-140.
101. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest 1993;91:1721-1730.
102. Sacco RL, Owen J, Mohr JP, Tatemichi TK, Grossman BA. Free protein S deficiency: A possible association with cerebrovascular occulsion. Stroke 1989;20:1657-1661.
103. D'Angelo SV, D'Angelo A, Kaufman C, Esmon CT, Comp PC. Acquired functional protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med 1987;107:42-47.
104. Boerger LM, Morris PC, Thurnau GR, Esmon CT, Comp PC. Oral contraceptives and gender affect protein S status. Blood 1987;69:692-694.
105. D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S: Protein S activity during oral anticoagulation, in liver disease and in disseminated intravascular coagulation. J Clin Invest 1988;81:1445-1454.
106. Girolami A, Simioni P, Lazzaro AR, Cordiano I. Severe arterial cerebral thrombosis in a patient with protein S deficiency (moderately reduced total and markedly reduced free protein S): A family study. Thromb Haemost 1989;61: 144-147.
107. Sheth SB, Carvalho AC. Protein S and C alterations in acutely ill patients. Am J Hematol 1991;36:14-19.
108. Scott BD, Esmon CT, Comp PC. The natural anticoagulant protein S is decreased in male smokers. Am Heart J 1991; 122:76-80.
109. Takahashi H, Tatewaki W, Wada K, Shibata A. Plasma protein S in disseminated intravascular coagulation, liver disease, collagen disease, diabetes mellitus, and under oral anticoagulant therapy. Clinica Chimica Acta 1989;182: 195-208.
110. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823.
111. Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benabadji M. Behç syndrome associated with protein S deficiency. Thromb Haemost 1992;67:1-3.
112. D'Angelo A, Valle PD, Crippa L, Pattarini E, Grimaldi LME, D'Angelo SV. Brief report: Autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993;328:1753-1757.
113. Prince HM, Thurlow PJ, Buchanan RC, Ibrahim KMA, Neeson PJ. Acquired protein S deficiency in a patient with systemic lupus erythematosus causing central retinal vein thrombosis. J Clin Pathol 1995;48:387-389.
114. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJH, Wouter ten Cate J. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
115. R5060. J Biol Chem 1995;270:4053-4057.
116. Billy D, Willems GM, Hemker HC, Lindhout T. Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes. J Biol Chem 1995;270:26883-26889.
117. R5060 by activated protein C. J Biol Chem 1995;270:27852-27858.
118. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 1. Thromb Haemost 1996;76:651-662.
119. Taylor FB Jr, Chang ACK, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon CT. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991;78:364-368.
120. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-647.
121. Gladson CL, Groncy P, Griffin JH. Coumarin necrosis, neonatal purpura fulminans, and protein C deficiency. Arch Dermatol 1987;123:1701a-1706a.
122. Branson H, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and a coumarin-responsive chronic relapsing purpura fulminans syndrome in a neonate. Lancet 1983;2: 1165-1168.
123. Dreyfus M, Masterson M, David M, Rivard GE, Muller F-M, Kreuz W, Beeg T, Minford A, Allgrove J, Cohen JD, Christoph J, Bergmann F, Mitchell VE, Haworth C, Nelson K, Schwarz HP. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Sem Thromb Hemost 1995;21:371-381.
124. Muller F-M, Ehrenthal W, Hafner G, Schranz D. Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate. Eur J Pediatr 1996;155:20-25.
125. Powars DR, Rogers ZR, Patch MJ, McGehee WG, Francis RB. Purpura fulminans in meningococcemia: Association with acquired deficiencies of proteins C and S. N Engl J Med 1987;317:571-574 (Letter).
126. Taylor FB Jr, Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res 1984;36:177-185.
127. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest 1987;79:918-925.
128. Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, Esmon CT. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78:357-363.
129. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995;126:646-652.
130. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-1593.
131. Gerson WT, Dickerman JD, Bovill EG, Golden E. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics 1993;91:418-422.
132. Hartman DL, Bernard GR, Heiterbrand JD, Yan SB, Fisher CJ. Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Med 1998;24:S77 (Abstract).
133. Bernard GR, Hartman DL, Helterbrand JD, Fisher CJ. Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis. Crit Care Med 1998;27:S4 (Abstract).
134. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994;153:3664-3672.
135. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, Salem HH. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 1995;60:1525-1532.
136. Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide. Glycobiology 1994;4:221-226.
137. Goldberg SL, Orthner CL, Yalisove BL, Elgart ML, Kessler CM. Skin necrosis following prolonged administration of coumarin in a patient with inherited protein S deficiency. Am J Hematol 1991;38:64-66.
138. Nguyen P, Reynaud J, Pouzol P, Munzer M, Richard O, Francois P. Varicella and thrombotic complications associated with transient protein C and protein S deficiencies in children. Eur J Pediatr 1994;153:646-649.